Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages 89-99

  Lehtinen, Matti ^a   Paavonen, Jorma ^b   Wheeler, Cosette M ^c   Jaisamrarn, Unnop ^d   Garland, Suzanne M ^e   Castellsagué, Xavier ^f   Skinner, S Rachel ^g,w   Apter, Dan ^h   Naud, Paulo ⁱ   Salmerón, Jorge ^j   Chow, Song Nan ^k   Kitchener, Henry ^l   Teixeira, Júlio C ^m   Hedrick, James ⁿ   Limson, Genara ^o   Szarewski, Anne ^p   Romanowski, Barbara ^q   Aoki, Fred Y ^r   Schwarz, Tino F ^s   Poppe, Willy A J ^t   De Carvalho, Newton S ^u   Germar, Maria Julieta V ^o   Peters, Klaus ^v   Mindel, Adrian ^w   De Sutter, Philippe ^x   Bosch, F Xavier ^f   David, Marie Pierre ^y   Descamps, Dominique ^y   Struyf, Frank ^y   Dubin, Gary ^z   more..

^a UNIVERSITY OF TAMPERE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h Vaestoliitto   (Finland)

ⁱ HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^j INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^k NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m UNIVERSITY OF CAMPINAS   (Brazil)

ⁿ Kentucky Pediatric Research Institute   (United States)

^o UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^p QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^q UNIVERSITY OF ALBERTA   (Canada)

^r UNIVERSITY OF MANITOBA   (Canada)

^s UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^t UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^u FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^v University of the Philippines College of Medicine Philippine General Hospital ^*  (Germany)

^w UNIVERSITY OF SYDNEY   (Australia)

^x UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^y GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^z GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUTOIMMUNE DISEASE; CANCER GRADING; CANCER IMMUNIZATION; CANCER PREVENTION; CHRONIC DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; TERATOGENICITY; UTERINE CERVIX ADENOCARCINOMA IN SITU; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE FACTORS; ALUMINUM HYDROXIDE; ASIA; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; NEOPLASM GRADING; NORTH AMERICA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SOUTH AMERICA; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84855300842     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70286-8     Document Type: Article

References (28)

1. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1651.
2. Crum CP The beginning of the end for cervical cancer?. N Engl J Med 2002, 347:1703-1705.
3. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170. for the HPV PATRICIA Study Group.
4. Paavonen J, Naud P, J Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. for the HPV PATRICIA Study Group.
5. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. Lancet 2009, 374:1975-1985. GlaxoSmithKline Vaccine HPV-007 Study Group.
6. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
7. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1916-1927. FUTURE II Study Group.
8. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325-339.
9. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007, 26:441-446.
10. Castle PE, Schiffman M, Wheeler CM, Solomon D Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009, 113:18-25.
11. Hakama M, Luostarinen T, Hakulinen T Survival of in situ carcinoma of cervix uteri: a 50-year follow-up in Finland. Int J Cancer 2004, 112:1072-1074.
12. Schiffman M, Herrero R, DeSalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337:76-84.
13. Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006, 17:517-521.
14. van Doorn L-J, Molijn A, Kleter B, Quint W, Colau B Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006, 44:3292-3298.
15. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011, for the HPV PATRICIA Study Group, published online Nov 9. 10.1016/S1470-2045(11)70287-X.
16. de Sanjosé S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey. Lancet Oncol 2010, 11:1048-1056. on behalf of the Retrospective International Survey and HPV Time Trends Study Group.
17. Gunnell AS, Ylitalo N, Sandin S, Sparén P, Adami HO, Ripatti S A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev 2007, 16:2641-2648.
18. Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005, 14:2191-2199.
19. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. JAMA 2007, 298:743-753.
20. Szarewski A, Poppe WAJ, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2011, published online Aug 19. 10.1002/ijc.26362.
21. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991, 265:472-477.
22. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005, 191:182-192.
23. Petäjä T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2010, published online Dec 28. 10.1002/ijc.25887.
24. French KM, Barnabas RV, Lehtinen M, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007, 96:514-518.
25. Kim JJ, Goldie SJ Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
26. Brotherton JML, Fridman M, May CL, Chappell G, Savile AM, Gertig DM Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
27. Läärä E, Day NE, Hakama M Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987, 1:1247-1249.
28. Harper DM, Nieminen P, Paavonen J, Lehtinen M Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis 2010, 10:594-595.